Page 1 | Search Results | Blood | American Society of Hematology

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa

Christen L. Ebens, MD MPH, John A McGrath, MD FRCP, FMedSci, Katsuto Tamai, MD PhD, Hovnanian Alain, MD PhD, John E. Wagner, MD, Megan Riddle, Douglas R Keene, BS, Todd E. DeFor, MS, Rebecca Tryon, MS, Mei Chen, PhD, David T Woodley, MD, Kristin Hook, MD, Jakub L Tolar, MD PhD

Blood (2018) 132 (Supplement 1): 2165.

https://doi.org/10.1182/blood-2018-99-113035

Published: 2018

Journal Articles

Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Jakub Tolar, MD, PhD, John A McGrath, MD, Mark J. Osborn, PhD, Douglas R Keene, BS, Kristen Hook, MD, Maria Hordinsky, MD, David Woodley, MD, Mei Chen, PhD, Alain Hovnanian, MD PhD, Katsuto Tamai, MD PhD, Bruce R. Blazar, MD, John E Wagner, MD

Blood (2015) 126 (23): 402.

https://doi.org/10.1182/blood.V126.23.402.402

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes

Jakub Tolar, MD, PhD, John A. McGrath, MD, FRCP, Mark J. Osborn, PhD, Kristen P. Hook, MD, Douglas R. Keene, BS, Maria K. Hordinsky, MD, Bruce R. Blazar, MD, John E. Wagner, MD

Blood (2012) 120 (21): 965.

https://doi.org/10.1182/blood.V120.21.965.965

Published: 2012

Journal Articles

First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement.

John E. Wagner, MD, Akemi Ishida-Yamamoto, Ph.D., John A McGrath, Ph.D., Maria Hordinsky, M.D., Douglas R Keene, B.S., Mark Osborn, B.S., Troy Lund, MD, PhD, Michelle Dolan, Bruce R. Blazar, MD, Jakub Tolar, MD, PhD

Blood (2009) 114 (22): 660.

https://doi.org/10.1182/blood.V114.22.660.660

Published: 2009

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa

Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes

First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement.

Email alerts

ASH Publications

American Society of Hematology

Update search

Reduced Intensity Conditioned Bone Marrow Transplant with Post-Transplant Cyclophosphamide and Donor-Derived Mesenchymal Stromal Cell Infusions for Recessive Dystrophic Epidermolysis Bullosa

Mucocutaneous Engraftment and Type VII Collagen (C7) Replacement after Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)

Allogeneic Hematopoietic Cell Transplantation for Severe Epidermolysis Bullosa: Impact of Conditioning Regimen and Stem Cell Source On Outcomes

First Use of Allogeneic Stem Cells in the Treatment of Recessive Dystrophic Epidermolysis Bullosa: Demonstration of Biochemical and Clinical Improvement.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only